A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

This phase 1/2 study assessed the safety, tolerability, and preliminary efficacy of the oral proteasome inhibitor (PI) ixazomib in patients with relapsed/refractory immunoglobulin light chain (AL) amyloidosis. Ixazomib was administered to adult patients with relapsed/refractory AL amyloidosis after...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Sanchorawala, Vaishali, Palladini, Giovanni, Kukreti, Vishal, Zonder, Jeffrey A., Cohen, Adam D., Seldin, David C., Dispenzieri, Angela, Jaccard, Arnaud, Schönland, Stefan O., Berg, Deborah, Yang, Huyuan, Gupta, Neeraj, Hui, Ai-Min, Comenzo, Raymond L., Merlini, Giampaolo
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2017
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6911836/
https://ncbi.nlm.nih.gov/pubmed/28550039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-03-771220
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares